Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Hydronidone Capsules in Healthy Chinese Subjects
NCT07262346Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of hydronidone in Liver Fibrosis (LF) (13 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 10 more. Started Dec 2025; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07262346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262346.